PDS Biotechnology (NASDAQ:PDSB) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a sell rating in a research report report published on Sunday,Wall Street Zen reports.

Several other analysts have also recently commented on PDSB. Weiss Ratings cut shares of PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 11th. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research note on Wednesday, August 26th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Down 3.0%

Shares of PDS Biotechnology stock opened at $0.74 on Friday. PDS Biotechnology has a 1 year low of $0.20 and a 1 year high of $1.55. The company has a market cap of $41.58 million, a P/E ratio of -1.16 and a beta of 1.46. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73. The stock has a 50-day moving average price of $0.50 and a 200 day moving average price of $0.79.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). As a group, analysts expect that PDS Biotechnology will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PDSB. BlackRock Inc. acquired a new stake in shares of PDS Biotechnology in the second quarter worth about $535,000. Bank of New York Mellon Corp bought a new stake in shares of PDS Biotechnology during the 2nd quarter worth about $60,000. Finally, Renaissance Technologies LLC increased its holdings in shares of PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after acquiring an additional 44,100 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.